On Invalid Date, Bolt Biotherapeutics (NASDAQ: BOLT) reported Q4 2023 earnings per share (EPS) of -$0.47, up 11.32% year over year. Total Bolt Biotherapeutics earnings for the quarter were -$17.90 million. In the same quarter last year, Bolt Biotherapeutics's earnings per share (EPS) was -$0.53.
As of Q1 2024, Bolt Biotherapeutics's earnings has grown year over year. Bolt Biotherapeutics's earnings in the past year totalled -$69.20 million.
What is BOLT's earnings date?
Bolt Biotherapeutics's earnings date is Invalid Date. Add BOLT to your watchlist to be reminded of BOLT's next earnings announcement.
What was BOLT's revenue last quarter?
On Invalid Date, Bolt Biotherapeutics (NASDAQ: BOLT) reported Q4 2023 revenue of $2.09 million up 48.05% year over year. In the same quarter last year, Bolt Biotherapeutics's revenue was $1.41 million.
What was BOLT's revenue growth in the past year?
As of Q1 2024, Bolt Biotherapeutics's revenue has grown 37.48% year over year. This is 128.14 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Bolt Biotherapeutics's revenue in the past year totalled $7.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.